Hengrui Medicine (01276.HK): HRS-1596 Tablets Receive Drug Clinical Trial Approval Notice

Zhito Finance APP news, Hengrui Pharmaceuticals (01276.HK) announced that recently, its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-1596 tablets, and will soon initiate clinical trials.